2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January 2025: Silent period 19 February 2025: Annual report 2024 13 March 2025 at 4.00 p.m.: Annual General Meeting ALK ...

Ensacove is approved for ALK-positive NSCLC patients who haven't received prior ALK-inhibitors, offering a new first-line treatment option. The eXALT3 trial showed Ensacove significantly improved ...

For safety, the most common adverse effects (AEs) related to ensartinib included rash (67.8%), increased aspartate aminotransferase (37.8%), increased alanine aminotransferase (48.3%), pruritus (26.6% ...

for the treatment of adults with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK inhibitor. In the trial, 290 patients were ...

Opens in a new tab or window The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the ...

The Tulsa, Oklahoma-based company said in a news release that the completion of MB-6 increases the company's fractionation capacity to more than one million bpd, “reducing the need for third ...

Cells were passaged at 70% confluence, and cells from passage 4 were used. To obtain a cell suspension, the surface of the culture bottle was washed with HyClone phosphate-buffered saline (PBS; Cytiva ...

Phosphate, also called phosphorus, is a mineral that helps the body build strong bones and maintain function. Phosphate helps cells stay healthy. It is a major component in adenosine triphosphate (ATP ...